Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia

Autor: Dansky, Hayes M. a, ⁎, Bloomfield, Daniel a, Gibbons, Patrice a, Liu, Sherry a, Sisk, Christine McCrary a, Tribble, Diane a, d, McKenney, James M. b, Littlejohn, Thomas W., III c, e, Mitchel, Yale a
Zdroj: In American Heart Journal 2011 162(4):708-716
Databáze: ScienceDirect
Externí odkaz: